Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00063-020-00750-8 http://scihub22266oqcxt.onion/10.1007/s00063-020-00750-8 33112981!7592182!33112981     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Klin+Intensivmed+Notfmed 2021 ; 116 (2): 138-145 Nephropedia Template TP {{tp|p=33112981|t=2021. Interdisziplinares COVID-Board bei SARS-CoV-2-getriggerter hyperferritinamischer Inflammation |pdf=|usr=}}{{33112981}} gab.com Text Interdisziplinares COVID-Board bei SARS-CoV-2-getriggerter hyperferritinamischer Inflammation JO: Med Klin Intensivmed Notfmed http://www.kidney.de/pget.php?&tw=1&pmid=33112981 #FOAvip BACKGROUND: Patients with severe COVID-19 develop hyperferritinemic inflammation, a rare sepsis-like immune dysregulation syndrome. METHODS: Stratified treatment decisions in a cross-location telemedical interdisciplinary case conference were assessed in this retrospective cohort study. A standardized treatment algorithm including continuous positive airway pressure and noninvasive ventilation was implemented. A locally developed COVID inflammation score (CIS) defined patients at risk for severe disease. Patients with life-threatening inflammation were offered off-label treatment with the immune modulator ruxolitinib. RESULTS: Between 4 March 2020 and 26 June 2020 COVID-19 patients (n?= 196) were treated. Median patient age (70 years) and comorbidity were high in interstudy comparison. Mortality in all patients was 17.3%. However, advance care planning statements and physician directives limited treatment intensity in 50% of the deceased patients. CIS monitoring of ruxolitinib-treated high-risk patients (n?= 20) on days 5, 7, and15 resulted in suppression of inflammation by 42% (15-70), 54% (15-77) and 60% (15-80). Here, mortality was 20% (4/20). Adjusted for patients with a maximum care directive including ICU, total mortality was 8.7% (17/196). CONCLUSION: Severe COVID-19 pneumonia with hyperferritinemic inflammation is related to macrophage activation syndrome-like sepsis. An interdisciplinary intensive care teleconference as a quality tool for ICUs is proposed to detect patients with rare sepsis-like syndromes. Twit Text FOAVip Interdisziplinares COVID-Board bei SARS-CoV-2-getriggerter hyperferritinamischer Inflammation ????Med Klin Intensivmed Notfmed http://www.kidney.de/pget.php?&tw=1&pmid=33112981 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33112981 #FOAvip English Wikipedia <ref>{{Cite pmid|33112981}}</ref> Interdisziplinares COVID-Board bei SARS-CoV-2-getriggerter hyperferritinamischer Inflammation #MMPMID33112981 La Rosee P; Bremer HC; La Rosee F; Mohm P; Hochhaus A; Gehrke I; Kumle B; Benzing A; Russo S Med Klin Intensivmed Notfmed 2021[Mar]; 116 (2): 138-145 PMID33112981show ga BACKGROUND: Patients with severe COVID-19 develop hyperferritinemic inflammation, a rare sepsis-like immune dysregulation syndrome. METHODS: Stratified treatment decisions in a cross-location telemedical interdisciplinary case conference were assessed in this retrospective cohort study. A standardized treatment algorithm including continuous positive airway pressure and noninvasive ventilation was implemented. A locally developed COVID inflammation score (CIS) defined patients at risk for severe disease. Patients with life-threatening inflammation were offered off-label treatment with the immune modulator ruxolitinib. RESULTS: Between 4 March 2020 and 26 June 2020 COVID-19 patients (n?= 196) were treated. Median patient age (70 years) and comorbidity were high in interstudy comparison. Mortality in all patients was 17.3%. However, advance care planning statements and physician directives limited treatment intensity in 50% of the deceased patients. CIS monitoring of ruxolitinib-treated high-risk patients (n?= 20) on days 5, 7, and15 resulted in suppression of inflammation by 42% (15-70), 54% (15-77) and 60% (15-80). Here, mortality was 20% (4/20). Adjusted for patients with a maximum care directive including ICU, total mortality was 8.7% (17/196). CONCLUSION: Severe COVID-19 pneumonia with hyperferritinemic inflammation is related to macrophage activation syndrome-like sepsis. An interdisciplinary intensive care teleconference as a quality tool for ICUs is proposed to detect patients with rare sepsis-like syndromes. |*COVID-19[MESH] |*SARS-CoV-2[MESH] |Aged[MESH] |Critical Care[MESH] |Humans[MESH] |Inflammation[MESH]Interdisziplinares COVID-Board bei SARS-CoV-2-getriggerter hyperferrit(epmc).pdf DeepDyve Pubget Overpricing